Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Nilsson · SciRah

Researcher profile · Semantic Scholar

M. Nilsson

Share profile

M. Nilsson — researcher profile on SciRah

h-index: 37
Works: 154
Citations: 7,157

Most-cited papers

Structure-based classification predicts drug response in EGFR-mutant NSCLC
J. Robichaux, X. Le, R. Vijayan, J. K. Hicks +29 more
2021Nature439 citations Open access
Semantic Scholar
Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-selective Kinase Inhibitor in Non-small Cell Lung Cancer
J. Robichaux, Y. Elamin, Zhi Tan, B. Carter +20 more
2018Nature Medicine416 citations Open access
Semantic Scholar
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Sonia A Patel, M. Nilsson, X. Le, T. Cascone +2 more
2022Clinical Cancer Research408 citations Open access
Semantic Scholar
Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC
X. Le, Sonam Puri, M. Negrao, M. Nilsson +20 more
2018Clinical Cancer Research340 citations Open access
Semantic Scholar
Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC.
X. Le, M. Nilsson, J. Goldman, M. Reck +8 more
2020Journal of Thoracic Oncology313 citations Open access
Semantic Scholar
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
J. Robichaux, Y. Elamin, R. Vijayan, M. Nilsson +27 more
2020Cancer Cell206 citations Open access
Semantic Scholar
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
M. Nilsson, Hui-Ying Sun, J. Robichaux, M. Pfeifer +20 more
2020Science Translational Medicine158 citations Open access
Semantic Scholar
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
S. Heeke, C. Gay, M. Estecio, H. Tran +38 more
2024Cancer Cell134 citations Open access
Semantic Scholar
Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target
X. Le, M. Negrao, A. Reuben, L. Federico +35 more
2020Journal of Thoracic Oncology111 citations Open access
Semantic Scholar
Poziotinib for EGFR exon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity
Y. Elamin, J. Robichaux, B. Carter, M. Altan +23 more
2022Cancer Cell96 citations Open access
Semantic Scholar
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
M. Nilsson, Yan Yang, S. Heeke, Sonia A Patel +23 more
2023Cancer Cell95 citations Open access
Semantic Scholar
β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers
M. Nilsson, X. Le, J. Heymach
2019Journal of Neuroimmune Pharmacology74 citations Open access
Semantic Scholar
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations
M. Negrao, V. Raymond, R. Lanman, J. Robichaux +18 more
2020Journal of Thoracic Oncology67 citations Open access
Semantic Scholar
Altered regulation of HIF-1α in naïve- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype
M. Nilsson, J. Robichaux, M. H. Herynk, T. Cascone +18 more
2020Journal of Thoracic Oncology61 citations Open access
Semantic Scholar
IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC
Sonia A Patel, M. Nilsson, Yan Yang, X. Le +13 more
2023Clinical Cancer Research45 citations Open access
Semantic Scholar
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology
C. Stewart, C. Gay, K. Ramkumar, K. Cargill +24 more
2021Journal of Thoracic Oncology44 citations Open access
Semantic Scholar
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology
C. Stewart, C. Gay, K. Ramkumar, K. Cargill +24 more
2020bioRxiv43 citations Open access
Semantic Scholar
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
M. Negrao, A. Reuben, J. Robichaux, X. Le +12 more
201841 citations
Semantic Scholar
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers
J. Gudikote, T. Cascone, A. Poteete, P. Sitthideatphaiboon +14 more
2021Journal of Biological Chemistry34 citations Open access
Semantic Scholar
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
M. Negrao, A. G. Paula, D. Molkentine, Laura D Hover +18 more
2025Clinical Cancer Research28 citations Open access
Semantic Scholar
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma
Jose A. Monteiro de Oliveira Novaes, Taghreed Hirz, I. Guijarro, M. Nilsson +13 more
2020Cancer Prevention Research26 citations Open access
Semantic Scholar
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
H. Udagawa, M. Nilsson, J. Robichaux, Jun-Qin He +14 more
2023Journal of Thoracic Oncology21 citations
Semantic Scholar
Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity
J. Robichaux, Y. Elamin, R. Vijayan, M. Nilsson +27 more
2019Cancer Cell17 citations Open access
Semantic Scholar
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs
M. Nilsson, X. Le, A. Poteete, Xiaoxing Yu +28 more
2026Journal of Thoracic Oncology16 citations Open access
Semantic Scholar
Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer
Sonia A Patel, M. H. Herynk, T. Cascone, B. Saigal +9 more
2021Journal of Thoracic Oncology15 citations Open access
Semantic Scholar
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
Xiaoke Liu, L. Hong, M. Nilsson, S. Hubert +12 more
2020Lung Cancer15 citations Open access
Semantic Scholar
MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
Y. Elamin, J. Robichaux, B. Carter, M. Altan +16 more
2019Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
V. Subbiah, T. Cascone, K. Hess, I. Subbiah +15 more
201814 citations
Semantic Scholar
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
D. Gomez, L. Byers, M. Nilsson, L. Diao +14 more
2018OncoTarget14 citations Open access
Semantic Scholar
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
L. Hong, W. Lewis, M. Nilsson, Sonia A Patel +18 more
2022Cancers13 citations Open access
Semantic Scholar
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
X. Le, M. Nilsson, J. Robichaux, J. Heymach
2021Cancer Cell13 citations Open access
Semantic Scholar
1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models
C. Stewart, C. Gay, K. Ramkumar, K. Cargill +15 more
2020Annals of Oncology9 citations Open access
Semantic Scholar
Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors
M. Nilsson, A. Poteete, H. Udagawa, Xiaoxing Yu +3 more
2023Cancer Research8 citations
Semantic Scholar
Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado
Ana Galán-Cobo, C. Stellrecht, E. Yilmaz, Chao-Xu Yang +17 more
2021Molecular Cancer Research8 citations Open access
Semantic Scholar
Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained
M. Nilsson, X. Le, Jun-Qin He, Xiaoxing Yu +6 more
2024Cancer Research6 citations
Semantic Scholar
The activity of EGFR CAR-NK and CAR-T cells against EGFR inhibitor-resistant NSCLC and drug-tolerant persister cells
Yan Yang, M. Nilsson, Xiaoxing Yu, A. Poteete +5 more
2025Clinical Cancer Research5 citations Open access
Semantic Scholar
Abstract 548: EGFR CAR-NK cells demonstrate potent activity against EGFR TKI resistant NSCLC
Yan Yang, M. Nilsson, Sonia A Patel, J. Robichaux +7 more
2022Cancer Research3 citations
Semantic Scholar
MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach
S. Heeke, C. Gay, M. Estecio, A. Stewart +17 more
2022Journal of Thoracic Oncology3 citations
Semantic Scholar
MA13.07 Structural Classification of Atypical EGFR Mutations Identifies 4 Major Subgroups with Distinct Patterns of Drug Sensitivity
J. Robichaux, X. Le, R. Vijayan, K. Hicks +21 more
20213 citations Open access
Semantic Scholar
IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components
M. Nilsson, H. Sun, J. Robichaux, L. Diao +16 more
2020Journal of Thoracic Oncology3 citations Open access
Semantic Scholar
Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
X. Le, Sonam Puri, M. Negrao, M. Nilsson +10 more
20183 citations
Semantic Scholar
Abstract 7025: Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance.
Yuji Shibata, M. Nilsson, Ximeng Liu, Li Cai +8 more
2026Cancer Research2 citations
Semantic Scholar
Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression
Madhurima Ghosh, Chao Wu, Abhisheka Kumar, M. Nilsson +13 more
2025Journal of Clinical Investigation2 citations Open access
Semantic Scholar
Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC
M. Negrao, D. Molkentine, A. G. Paula, Laura D Hover +15 more
2024Cancer Research2 citations
Semantic Scholar
Abstract 1229: BDTX-1535: A MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving molecular landscape of EGFR mutant NSCLC
E. Dardenne, M. O'Connor, M. Nilsson, Jun-Qin He +4 more
2024Cancer Research2 citations
Semantic Scholar
Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions
M. Nilsson, Z. Mounir, L. Musib, Jun-Qin He +8 more
2024Cancer Research2 citations
Semantic Scholar
Abstract 6087: Mutation and co-mutation landscape ofERBB2 alterations in advanced NSCLC
L. Hong, L. Drusbosky, Yin-Yan Wang, Yu Xiong +6 more
2023Cancer Research2 citations
Semantic Scholar
Abstract 1182: Molecular landscape and ErbB family signaling in NRG fusion NSCLC: Therapeutic implications for pan-ErbB family inhibitors
H. Udagawa, J. Robichaux, Y. Elamin, Jun-Qin He +2 more
2022Cancer Research2 citations
Semantic Scholar
Abstract 1827: CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance
M. Nilsson, Yan Yang, Sonia A Patel, S. Heeke +19 more
2022Cancer Research2 citations
Semantic Scholar
Erratum: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (Science Translational Medicine DOI: 10.1126/scitranslmed.aao4307)
M. Nilsson, H. Sun, L. Diao, P. Tong +21 more
20192 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Heymach×43
Invite
J. Heymach — researcher profile on SciRah
X. Le×24
Invite
X. Le — researcher profile on SciRah
J. Robichaux×22
Invite
J. Robichaux — researcher profile on SciRah
A. Poteete×19
Invite
A. Poteete — researcher profile on SciRah

×19

Invite

L. Diao — researcher profile on SciRah

Invite

Jun-Qin He — researcher profile on SciRah

Invite

Y. Elamin — researcher profile on SciRah

Invite

Jing Wang — researcher profile on SciRah

Invite

M. Negrao — researcher profile on SciRah

Invite

S. Heeke — researcher profile on SciRah

Invite

D. Gibbons — researcher profile on SciRah

Xiaoxing Yu×12

Invite

Xiaoxing Yu — researcher profile on SciRah